Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,437,696 shares of CYTK stock, worth $599 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,437,696
Previous 9,997,076
14.41%
Holding current value
$599 Million
Previous $701 Million
11.59%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$768 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$426 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$393 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$343 Million0.02% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.58MShares$239 Million29.98% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.93B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...